About This Fund
Invivo Ventures FCR is the first flagship venture capital fund of Invivo Partners, a Barcelona-based life sciences investment firm co-founded by Dr. Luis Pareras and Albert Ferrer. Registered with Spain's Comisión Nacional del Mercado de Valores (CNMV) in March 2019 and structured as a Fondo de Capital Riesgo (FCR) under Spanish private capital regulation, the fund targets early-stage life sciences companies in Spain and across the Ibero-European ecosystem. Institutional investors backing the fund include the European Investment Fund (EIF), Instituto de Crédito Oficial (ICO), Institut Català de Finances (ICF), Institut Valencià de Finances (IVF), and the Ajuntament de Barcelona, alongside a majority private investor base representing sustained confidence in Invivo Partners' early-stage life sciences thesis.
Invivo Ventures FCR focuses on technology transfer-stage biotechnology and medical device companies, investing at the earliest commercial stages where proof-of-concept in animal models (for biotech) or a near-market prototype (for medical devices and digital health) has been established. The fund concentrates on Spain's rich academic and hospital-based research ecosystem — including spinouts from institutions such as Hospital Clínic-IDIBAPS Barcelona and leading Spanish universities — to identify and back foundational platforms in oncology, cell and gene therapy, immunotherapy, and other high-value therapeutic areas. Portfolio construction targets a diversified set of platforms across therapeutic modalities and preclinical stages, with the conviction that foundational biology backed by rigorous science provides the strongest risk-adjusted returns in early-stage life sciences investing. Investment sizes range from initial seed tickets to Series A follow-on rounds, with deep scientific due diligence performed by a team with direct biomedical research backgrounds.
Invivo Partners grew its platform from Invivo Ventures FCR into a family of funds with assets under management exceeding €150 million across three vehicles, demonstrating the firm's ability to raise institutional capital and deliver portfolio-level scientific and financial progress. Portfolio companies backed through Invivo Ventures FCR and successor vehicles include EsoBiotec (an in vivo cell engineering platform for cancer therapy), OneChain Immunotherapeutics (a cancer immunotherapy company), and Telum Therapeutics — all progressing through rigorous preclinical and early clinical milestones. The success of Invivo Ventures FCR led the firm to launch Invivo Ventures III targeting €100 million in life sciences and, subsequently, Invivo Ventures AI targeting a further €100 million at the intersection of AI and biotechnology, establishing Invivo Partners as the leading early-stage life sciences VC platform in Spain.